At a glance
ClinicalIndex Comparison RecordN/ACompleted· 157 enrolled
Drug / intervention
etanercept +1 moredrug
Likely dose
etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Rheumatoid Arthritis Patients Treated With Etanercept (Enbrel (Registered))
In Brief
An observational study evaluating etanercept for Rheumatoid Arthritis. Completed, enrolled 157 participants across 35 sites.
Detailed Summary
Defining Which Remission Criterion at Month 6 Predicts Remission at Month 12 in a Real Life Clinical Practice, in a Cohort of Rheumatoid Arthritis Patients Treated with Etanercept
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartAug 2014
Primary CompletionApr 2017
TodayJul 2026
First PostedJul 29, 2014
Enrollment StartAug 12, 2014
Primary CompletionApr 24, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.9 years ago
Interventions
etanerceptdrug
etanercept 1 x 50 mg/week or 2 x 25mg/week
etanerceptdrug
etanercept 1 x 50 mg/week or 2 x 25mg/week